A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Status
Active
Cancer Type
Breast Cancer
Trial Phase
Phase III
Eligibility
18 and over, Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01610284
Protocol IDs
CBKM120F2302 (primary)
2011-005524-17
Study Sponsor
Novartis Pharmaceuticals Corporation

Summary

The purpose of this study is to determine wether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor.